中生尚健生物医药

Sino-Health Biopharmaceutical is a clinical-stage Chinese biotechnology company dedicated to the discovery and development of innovative antibody-based therapeutics for oncology. The company utilizes its proprietary technology platforms to engineer next-generation biologics, including bispecific antibodies and fusion proteins designed to address unmet medical needs in cancer treatment. Its lead candidates target well-validated pathways such as EGFR, c-Met, and PD-L1, with several programs currently undergoing clinical evaluation in patients with advanced solid tumors. Sino-Health aims to provide more effective and precise treatment options for cancer patients globally through its robust pipeline of innovative medicines.